Relay Therapeutics, Inc.

Healthcare

NASDAQ:RLAY · NASDAQ Global Market

Market Cap $2.59B Beta 1.75 P/E (TTM) -9.8

$14.81 +4.00%

+$0.57 today

52W Low $2.98High $17.47

Vol 1.77M · Avg 3.70M

EPS (TTM)-$1.52

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+359.94%

Period High

$16.80

Period Low

$3.06

Latest

$14.81

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

$1.62B

Inhibrx Biosciences, Inc.

NASDAQ:INBX

$1.35B

Immatics N.V.

NASDAQ:IMTX

$1.26B

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

$1.21B

Nektar Therapeutics

NASDAQ:NKTR

$1.16B

CureVac N.V.

CVAC

$1.05B

Zenas BioPharma, Inc.

NASDAQ:ZBIO

$883.93M

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

$856.09M

Sana Biotechnology, Inc.

NASDAQ:SANA

$745.82M

Upstream Bio, Inc.

UPB

$331.96M

What is the latest RLAY filing?

The latest filing shown is 4 dated Jun 10, 2026.

How many recent filings does RLAY have?

Intrinsic Alpha currently shows 20 recent filings for RLAY.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.